Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients

Reuters01-12

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients

Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602851415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602851415","market":"fut","top_or_hot":-1,"title":"Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VKTX","symbol_name":"Viking Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5TgZPP:1","article_id":"2602851415","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602851415","pubTimestamp":1768219379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VKTX":"Viking Therapeutics, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4599":"减肥药"},"translate_title":"Viking Therapeutics报告2期试验显示VK2735可使肥胖患者体重减轻高达14.7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics Reports Phase 2 Trial Shows VK2735 Achieves Up to 14.7% Weight Loss in Obesity Patients\n    \n\n        Viking Therapeutics Inc. has announced the publication of results from its Phase 2 VENTURE clinical trial evaluating VK2735, a dual GLP-1/GIP receptor agonist, in the journal Obesity. The study reported weight loss of up to 14.7% from baseline after 13 weeks of treatment in patients with obesity, with no plateau observed. VK2735 was generally well-tolerated, with most adverse events categorized as mild or moderate. The results have already been presented and published. VK2735 is currently being evaluated in two Phase 3 studies, VANQUISH-1 and VANQUISH-2, which are assessing the efficacy and safety of weekly subcutaneous dosing in adults with obesity or overweight, with or without type 2 diabetes. Enrollment for VANQUISH-1 has been completed, while VANQUISH-2 is expected to complete enrollment in the first quarter of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA60751) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602851415","isCrawlerRequest":true}